Telbivudine  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
chronic  ||| S:33 E:41 ||| JJ
hepatitis  ||| S:41 E:51 ||| NNP
B  ||| S:51 E:53 ||| NNP
infection  ||| S:53 E:63 ||| VBD
This  ||| S:63 E:68 ||| DT
paper  ||| S:68 E:74 ||| NN
presents  ||| S:74 E:83 ||| VBZ
a  ||| S:83 E:85 ||| DT
summary  ||| S:85 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
the  ||| S:96 E:100 ||| DT
evidence  ||| S:100 E:109 ||| NN
review  ||| S:109 E:116 ||| NN
group  ||| S:116 E:122 ||| NN
( ||| S:122 E:123 ||| -LRB-
ERG ||| S:123 E:126 ||| NNP
)  ||| S:126 E:128 ||| -RRB-
report  ||| S:128 E:135 ||| NN
into  ||| S:135 E:140 ||| IN
the  ||| S:140 E:144 ||| DT
clinical  ||| S:144 E:153 ||| JJ
effectiveness  ||| S:153 E:167 ||| NN
and  ||| S:167 E:171 ||| CC
cost-effectiveness  ||| S:171 E:190 ||| JJ
of  ||| S:190 E:193 ||| IN
telbivudine  ||| S:193 E:205 ||| NN
for  ||| S:205 E:209 ||| IN
the  ||| S:209 E:213 ||| DT
treatment  ||| S:213 E:223 ||| NN
of  ||| S:223 E:226 ||| IN
chronic  ||| S:226 E:234 ||| JJ
hepatitis  ||| S:234 E:244 ||| NNP
B  ||| S:244 E:246 ||| NNP
( ||| S:246 E:247 ||| -LRB-
CHB ||| S:247 E:250 ||| NNP
)  ||| S:250 E:252 ||| -RRB-
in  ||| S:252 E:255 ||| IN
adults  ||| S:255 E:262 ||| NNS
based  ||| S:262 E:268 ||| VBN
upon  ||| S:268 E:273 ||| IN
a  ||| S:273 E:275 ||| DT
review  ||| S:275 E:282 ||| NN
of  ||| S:282 E:285 ||| IN
the  ||| S:285 E:289 ||| DT
manufacturer ||| S:289 E:301 ||| NN
's  ||| S:301 E:304 ||| POS
submission  ||| S:304 E:315 ||| NN
to  ||| S:315 E:318 ||| TO
the  ||| S:318 E:322 ||| DT
National  ||| S:322 E:331 ||| NNP
Institute  ||| S:331 E:341 ||| NNP
for  ||| S:341 E:345 ||| IN
Health  ||| S:345 E:352 ||| NNP
and  ||| S:352 E:356 ||| CC
Clinical  ||| S:356 E:365 ||| NNP
Excellence  ||| S:365 E:376 ||| NNP
( ||| S:376 E:377 ||| -LRB-
NICE ||| S:377 E:381 ||| NNP
)  ||| S:381 E:383 ||| -RRB-
as  ||| S:383 E:386 ||| IN
part  ||| S:386 E:391 ||| NN
of  ||| S:391 E:394 ||| IN
the  ||| S:394 E:398 ||| DT
single  ||| S:398 E:405 ||| JJ
technology  ||| S:405 E:416 ||| NN
appraisal  ||| S:416 E:426 ||| NN
( ||| S:426 E:427 ||| -LRB-
STA ||| S:427 E:430 ||| NNP
)  ||| S:430 E:432 ||| -RRB-
process ||| S:432 E:439 ||| NN
.  ||| S:439 E:441 ||| .
The  ||| S:441 E:445 ||| DT
submission ||| S:445 E:455 ||| NN
's  ||| S:455 E:458 ||| POS
evidence  ||| S:458 E:467 ||| NN
came  ||| S:467 E:472 ||| VBD
from  ||| S:472 E:477 ||| IN
one  ||| S:477 E:481 ||| CD
randomised  ||| S:481 E:492 ||| NNS
controlled  ||| S:492 E:503 ||| VBN
trial  ||| S:503 E:509 ||| NN
( ||| S:509 E:510 ||| -LRB-
RCT ||| S:510 E:513 ||| NNP
)  ||| S:513 E:515 ||| -RRB-
( ||| S:515 E:516 ||| -LRB-
GLOBE ||| S:516 E:521 ||| NNP
)  ||| S:521 E:523 ||| -RRB-
of  ||| S:523 E:526 ||| IN
reasonable  ||| S:526 E:537 ||| JJ
methodological  ||| S:537 E:552 ||| JJ
quality  ||| S:552 E:560 ||| NN
comparing  ||| S:560 E:570 ||| VBG
telbivudine  ||| S:570 E:582 ||| NN
with  ||| S:582 E:587 ||| IN
lamivudine ||| S:587 E:597 ||| NN
.  ||| S:597 E:599 ||| .
One  ||| S:599 E:603 ||| CD
other  ||| S:603 E:609 ||| JJ
RCT  ||| S:609 E:613 ||| NN
that  ||| S:613 E:618 ||| WDT
appeared  ||| S:618 E:627 ||| VBD
to  ||| S:627 E:630 ||| TO
meet  ||| S:630 E:635 ||| VB
the  ||| S:635 E:639 ||| DT
inclusion  ||| S:639 E:649 ||| NN
criteria  ||| S:649 E:658 ||| NNS
was  ||| S:658 E:662 ||| VBD
excluded  ||| S:662 E:671 ||| VBN
from  ||| S:671 E:676 ||| IN
the  ||| S:676 E:680 ||| DT
submission ||| S:680 E:690 ||| NN
.  ||| S:690 E:692 ||| .
For  ||| S:692 E:696 ||| IN
the  ||| S:696 E:700 ||| DT
primary  ||| S:700 E:708 ||| JJ
outcome  ||| S:708 E:716 ||| NN
of  ||| S:716 E:719 ||| IN
therapeutic  ||| S:719 E:731 ||| JJ
response  ||| S:731 E:740 ||| NN
telbivudine  ||| S:740 E:752 ||| NNS
was  ||| S:752 E:756 ||| VBD
statistically  ||| S:756 E:770 ||| RB
superior  ||| S:770 E:779 ||| JJ
to  ||| S:779 E:782 ||| TO
lamivudine  ||| S:782 E:793 ||| VB
at  ||| S:793 E:796 ||| IN
weeks  ||| S:796 E:802 ||| NNS
52  ||| S:802 E:805 ||| CD
and  ||| S:805 E:809 ||| CC
104  ||| S:809 E:813 ||| CD
for  ||| S:813 E:817 ||| IN
hepatitis  ||| S:817 E:827 ||| NNP
B  ||| S:827 E:829 ||| NNP
e  ||| S:829 E:831 ||| SYM
antigen  ||| S:831 E:839 ||| FW
( ||| S:839 E:840 ||| -LRB-
HBeAg ||| S:840 E:845 ||| NNP
) ||| S:845 E:846 ||| -RRB-
-positive  ||| S:846 E:856 ||| JJ
patients ||| S:856 E:864 ||| NNS
,  ||| S:864 E:866 ||| ,
and  ||| S:866 E:870 ||| CC
at  ||| S:870 E:873 ||| IN
week  ||| S:873 E:878 ||| NN
104  ||| S:878 E:882 ||| CD
for  ||| S:882 E:886 ||| IN
HBeAg-negative  ||| S:886 E:901 ||| JJ
patients ||| S:901 E:909 ||| NNS
.  ||| S:909 E:911 ||| .
There  ||| S:911 E:917 ||| EX
were  ||| S:917 E:922 ||| VBD
statistically  ||| S:922 E:936 ||| RB
significant  ||| S:936 E:948 ||| JJ
differences  ||| S:948 E:960 ||| NNS
in  ||| S:960 E:963 ||| IN
favour  ||| S:963 E:970 ||| NN
of  ||| S:970 E:973 ||| IN
telbivudine  ||| S:973 E:985 ||| NN
for  ||| S:985 E:989 ||| IN
some  ||| S:989 E:994 ||| DT
secondary  ||| S:994 E:1004 ||| JJ
outcomes  ||| S:1004 E:1013 ||| NNS
at  ||| S:1013 E:1016 ||| IN
2  ||| S:1016 E:1018 ||| CD
years  ||| S:1018 E:1024 ||| NNS
including  ||| S:1024 E:1034 ||| VBG
hepatitis  ||| S:1034 E:1044 ||| NNP
B  ||| S:1044 E:1046 ||| NNP
virus  ||| S:1046 E:1052 ||| NN
( ||| S:1052 E:1053 ||| -LRB-
HBV ||| S:1053 E:1056 ||| NNP
)  ||| S:1056 E:1058 ||| -RRB-
DNA  ||| S:1058 E:1062 ||| NNP
reduction ||| S:1062 E:1071 ||| NN
,  ||| S:1071 E:1073 ||| ,
HBV  ||| S:1073 E:1077 ||| NNP
DNA  ||| S:1077 E:1081 ||| NNP
non-detectability  ||| S:1081 E:1099 ||| NNP
and  ||| S:1099 E:1103 ||| CC
alanine  ||| S:1103 E:1111 ||| JJ
aminotransferase  ||| S:1111 E:1128 ||| NNS
normalisation  ||| S:1128 E:1142 ||| VBP
though  ||| S:1142 E:1149 ||| RB
not  ||| S:1149 E:1153 ||| RB
for  ||| S:1153 E:1157 ||| IN
HBeAg-positive  ||| S:1157 E:1172 ||| JJ
patients ||| S:1172 E:1180 ||| NNS
.  ||| S:1180 E:1182 ||| .
In  ||| S:1182 E:1185 ||| IN
HBeAg-positive  ||| S:1185 E:1200 ||| JJ
patients  ||| S:1200 E:1209 ||| NNS
there  ||| S:1209 E:1215 ||| EX
was  ||| S:1215 E:1219 ||| VBD
no  ||| S:1219 E:1222 ||| DT
significant  ||| S:1222 E:1234 ||| JJ
difference  ||| S:1234 E:1245 ||| NN
between  ||| S:1245 E:1253 ||| IN
treatment  ||| S:1253 E:1263 ||| NN
groups  ||| S:1263 E:1270 ||| NNS
for  ||| S:1270 E:1274 ||| IN
HBeAg  ||| S:1274 E:1280 ||| JJ
loss  ||| S:1280 E:1285 ||| NN
or  ||| S:1285 E:1288 ||| CC
seroconversion  ||| S:1288 E:1303 ||| NN
at  ||| S:1303 E:1306 ||| IN
any  ||| S:1306 E:1310 ||| DT
time  ||| S:1310 E:1315 ||| NN
point ||| S:1315 E:1320 ||| NN
.  ||| S:1320 E:1322 ||| .
The  ||| S:1322 E:1326 ||| DT
incidence  ||| S:1326 E:1336 ||| NN
of  ||| S:1336 E:1339 ||| IN
adverse  ||| S:1339 E:1347 ||| JJ
events  ||| S:1347 E:1354 ||| NNS
was  ||| S:1354 E:1358 ||| VBD
similar  ||| S:1358 E:1366 ||| JJ
between  ||| S:1366 E:1374 ||| IN
treatments ||| S:1374 E:1384 ||| NNS
.  ||| S:1384 E:1386 ||| .
Two  ||| S:1386 E:1390 ||| CD
RCTs  ||| S:1390 E:1395 ||| JJ
comparing  ||| S:1395 E:1405 ||| JJ
entecavir  ||| S:1405 E:1415 ||| NN
with  ||| S:1415 E:1420 ||| IN
lamivudine  ||| S:1420 E:1431 ||| NN
were  ||| S:1431 E:1436 ||| VBD
included  ||| S:1436 E:1445 ||| VBN
in  ||| S:1445 E:1448 ||| IN
the  ||| S:1448 E:1452 ||| DT
indirect  ||| S:1452 E:1461 ||| JJ
comparison ||| S:1461 E:1471 ||| NN
;  ||| S:1471 E:1473 ||| :
however ||| S:1473 E:1480 ||| RB
,  ||| S:1480 E:1482 ||| ,
this  ||| S:1482 E:1487 ||| DT
was  ||| S:1487 E:1491 ||| VBD
poorly  ||| S:1491 E:1498 ||| RB
conducted  ||| S:1498 E:1508 ||| VBN
and  ||| S:1508 E:1512 ||| CC
the  ||| S:1512 E:1516 ||| DT
results  ||| S:1516 E:1524 ||| NNS
should  ||| S:1524 E:1531 ||| MD
be  ||| S:1531 E:1534 ||| VB
treated  ||| S:1534 E:1542 ||| VBN
with  ||| S:1542 E:1547 ||| IN
caution ||| S:1547 E:1554 ||| NN
.  ||| S:1554 E:1556 ||| .
The  ||| S:1556 E:1560 ||| DT
manufacturer  ||| S:1560 E:1573 ||| NN
developed  ||| S:1573 E:1583 ||| VBD
two  ||| S:1583 E:1587 ||| CD
economic  ||| S:1587 E:1596 ||| JJ
models  ||| S:1596 E:1603 ||| NNS
to  ||| S:1603 E:1606 ||| TO
determine  ||| S:1606 E:1616 ||| VB
the  ||| S:1616 E:1620 ||| DT
cost-effectiveness  ||| S:1620 E:1639 ||| JJ
of  ||| S:1639 E:1642 ||| IN
telbivudine ||| S:1642 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
Evidence  ||| S:1655 E:1664 ||| NN
on  ||| S:1664 E:1667 ||| IN
the  ||| S:1667 E:1671 ||| DT
efficacy  ||| S:1671 E:1680 ||| NN
of  ||| S:1680 E:1683 ||| IN
telbivudine  ||| S:1683 E:1695 ||| NN
and  ||| S:1695 E:1699 ||| CC
lamivudine  ||| S:1699 E:1710 ||| NNS
was  ||| S:1710 E:1714 ||| VBD
taken  ||| S:1714 E:1720 ||| VBN
from  ||| S:1720 E:1725 ||| IN
the  ||| S:1725 E:1729 ||| DT
GLOBE  ||| S:1729 E:1735 ||| NNP
trial ||| S:1735 E:1740 ||| NN
;  ||| S:1740 E:1742 ||| :
efficacy  ||| S:1742 E:1751 ||| NN
of  ||| S:1751 E:1754 ||| IN
adefovir  ||| S:1754 E:1763 ||| NN
was  ||| S:1763 E:1767 ||| VBD
based  ||| S:1767 E:1773 ||| VBN
on  ||| S:1773 E:1776 ||| IN
assumption ||| S:1776 E:1786 ||| NN
.  ||| S:1786 E:1788 ||| .
There  ||| S:1788 E:1794 ||| EX
was  ||| S:1794 E:1798 ||| VBD
a  ||| S:1798 E:1800 ||| DT
lack  ||| S:1800 E:1805 ||| NN
of  ||| S:1805 E:1808 ||| IN
critical  ||| S:1808 E:1817 ||| JJ
assessment  ||| S:1817 E:1828 ||| NN
and  ||| S:1828 E:1832 ||| CC
assurance  ||| S:1832 E:1842 ||| NN
of  ||| S:1842 E:1845 ||| IN
the  ||| S:1845 E:1849 ||| DT
quality  ||| S:1849 E:1857 ||| NN
of  ||| S:1857 E:1860 ||| IN
the  ||| S:1860 E:1864 ||| DT
data  ||| S:1864 E:1869 ||| NNS
used  ||| S:1869 E:1874 ||| VBN
to  ||| S:1874 E:1877 ||| TO
populate  ||| S:1877 E:1886 ||| VB
the  ||| S:1886 E:1890 ||| DT
models ||| S:1890 E:1896 ||| NNS
.  ||| S:1896 E:1898 ||| .
The  ||| S:1898 E:1902 ||| DT
manufacturer  ||| S:1902 E:1915 ||| NN
concluded  ||| S:1915 E:1925 ||| VBD
that  ||| S:1925 E:1930 ||| DT
telbivudine  ||| S:1930 E:1942 ||| NN
is  ||| S:1942 E:1945 ||| VBZ
a  ||| S:1945 E:1947 ||| DT
cost-effective  ||| S:1947 E:1962 ||| JJ
option  ||| S:1962 E:1969 ||| NN
compared  ||| S:1969 E:1978 ||| VBN
with  ||| S:1978 E:1983 ||| IN
lamivudine  ||| S:1983 E:1994 ||| NNS
using  ||| S:1994 E:2000 ||| VBG
evidence  ||| S:2000 E:2009 ||| NN
from  ||| S:2009 E:2014 ||| IN
the  ||| S:2014 E:2018 ||| DT
viral  ||| S:2018 E:2024 ||| JJ
load  ||| S:2024 E:2029 ||| NN
model  ||| S:2029 E:2035 ||| NN
[ ||| S:2035 E:2036 ||| -LRB-
HBeAg-positive  ||| S:2036 E:2051 ||| JJ
patients ||| S:2051 E:2059 ||| NNS
/ ||| S:2059 E:2060 ||| VBP
HBeAg-negative  ||| S:2060 E:2075 ||| JJ
patients ||| S:2075 E:2083 ||| NNS
:  ||| S:2083 E:2085 ||| :
mean  ||| S:2085 E:2090 ||| VB
incremental  ||| S:2090 E:2102 ||| JJ
cost  ||| S:2102 E:2107 ||| NN
19,087  ||| S:2107 E:2114 ||| CD
pounds ||| S:2114 E:2120 ||| CD
/ ||| S:2120 E:2121 ||| CD
49,003  ||| S:2121 E:2128 ||| CD
pounds ||| S:2128 E:2134 ||| NNS
,  ||| S:2134 E:2136 ||| ,
mean  ||| S:2136 E:2141 ||| VBP
quality-adjusted  ||| S:2141 E:2158 ||| JJ
life-year  ||| S:2158 E:2168 ||| NN
( ||| S:2168 E:2169 ||| -LRB-
QALY ||| S:2169 E:2173 ||| NNP
)  ||| S:2173 E:2175 ||| -RRB-
gain  ||| S:2175 E:2180 ||| NN
1.30 ||| S:2180 E:2184 ||| CD
/ ||| S:2184 E:2185 ||| CD
4.67 ||| S:2185 E:2189 ||| CD
,  ||| S:2189 E:2191 ||| ,
incremental  ||| S:2191 E:2203 ||| JJ
cost-effectiveness  ||| S:2203 E:2222 ||| JJ
ratio  ||| S:2222 E:2228 ||| NN
( ||| S:2228 E:2229 ||| -LRB-
ICER ||| S:2229 E:2233 ||| NNP
)  ||| S:2233 E:2235 ||| -RRB-
14,665  ||| S:2235 E:2242 ||| FW
pounds ||| S:2242 E:2248 ||| FW
/ ||| S:2248 E:2249 ||| FW
10,497  ||| S:2249 E:2256 ||| FW
pounds  ||| S:2256 E:2263 ||| FW
per  ||| S:2263 E:2267 ||| FW
QALY ||| S:2267 E:2271 ||| FW
] ||| S:2271 E:2272 ||| -RRB-
.  ||| S:2272 E:2274 ||| .
Resubmitted  ||| S:2274 E:2286 ||| JJ
results  ||| S:2286 E:2294 ||| NNS
after  ||| S:2294 E:2300 ||| IN
a  ||| S:2300 E:2302 ||| DT
request  ||| S:2302 E:2310 ||| NN
for  ||| S:2310 E:2314 ||| IN
clarification  ||| S:2314 E:2328 ||| NN
by  ||| S:2328 E:2331 ||| IN
the  ||| S:2331 E:2335 ||| DT
ERG  ||| S:2335 E:2339 ||| NNP
gave  ||| S:2339 E:2344 ||| VBD
less  ||| S:2344 E:2349 ||| RBR
favourable  ||| S:2349 E:2360 ||| JJ
ICERs  ||| S:2360 E:2366 ||| NN
( ||| S:2366 E:2367 ||| -LRB-
HBeAg-positive  ||| S:2367 E:2382 ||| JJ
patients ||| S:2382 E:2390 ||| NNS
/ ||| S:2390 E:2391 ||| VBP
HBeAg-negative  ||| S:2391 E:2406 ||| JJ
patients ||| S:2406 E:2414 ||| NNS
:  ||| S:2414 E:2416 ||| :
mean  ||| S:2416 E:2421 ||| VB
incremental  ||| S:2421 E:2433 ||| JJ
cost  ||| S:2433 E:2438 ||| NN
23,983  ||| S:2438 E:2445 ||| CD
pounds ||| S:2445 E:2451 ||| CD
/ ||| S:2451 E:2452 ||| CD
41,910  ||| S:2452 E:2459 ||| CD
pounds ||| S:2459 E:2465 ||| NNS
,  ||| S:2465 E:2467 ||| ,
mean  ||| S:2467 E:2472 ||| VBP
QALY  ||| S:2472 E:2477 ||| JJ
gain  ||| S:2477 E:2482 ||| NN
1.56 ||| S:2482 E:2486 ||| CD
/ ||| S:2486 E:2487 ||| CD
2.07 ||| S:2487 E:2491 ||| CD
,  ||| S:2491 E:2493 ||| ,
ICER  ||| S:2493 E:2498 ||| FW
15,377  ||| S:2498 E:2505 ||| FW
pounds ||| S:2505 E:2511 ||| FW
/ ||| S:2511 E:2512 ||| FW
20,256  ||| S:2512 E:2519 ||| FW
pounds  ||| S:2519 E:2526 ||| FW
per  ||| S:2526 E:2530 ||| FW
QALY ||| S:2530 E:2534 ||| FW
) ||| S:2534 E:2535 ||| -RRB-
.  ||| S:2535 E:2537 ||| .
The  ||| S:2537 E:2541 ||| DT
manufacturer  ||| S:2541 E:2554 ||| NN
concluded  ||| S:2554 E:2564 ||| VBD
that  ||| S:2564 E:2569 ||| DT
telbivudine  ||| S:2569 E:2581 ||| NN
is  ||| S:2581 E:2584 ||| VBZ
a  ||| S:2584 E:2586 ||| DT
cost-effective  ||| S:2586 E:2601 ||| JJ
option  ||| S:2601 E:2608 ||| NN
( ||| S:2608 E:2609 ||| -LRB-
on  ||| S:2609 E:2612 ||| IN
its  ||| S:2612 E:2616 ||| PRP$
own  ||| S:2616 E:2620 ||| JJ
or  ||| S:2620 E:2623 ||| CC
followed  ||| S:2623 E:2632 ||| VBN
by  ||| S:2632 E:2635 ||| IN
adefovir ||| S:2635 E:2643 ||| CD
)  ||| S:2643 E:2645 ||| -RRB-
for  ||| S:2645 E:2649 ||| IN
patients  ||| S:2649 E:2658 ||| NNS
who  ||| S:2658 E:2662 ||| WP
have  ||| S:2662 E:2667 ||| VBP
developed  ||| S:2667 E:2677 ||| VBN
resistance  ||| S:2677 E:2688 ||| NN
to  ||| S:2688 E:2691 ||| TO
first-line  ||| S:2691 E:2702 ||| JJ
telbivudine  ||| S:2702 E:2714 ||| JJ
treatment ||| S:2714 E:2723 ||| NN
;  ||| S:2723 E:2725 ||| :
however ||| S:2725 E:2732 ||| RB
,  ||| S:2732 E:2734 ||| ,
the  ||| S:2734 E:2738 ||| DT
presentation  ||| S:2738 E:2751 ||| NN
of  ||| S:2751 E:2754 ||| IN
the  ||| S:2754 E:2758 ||| DT
results  ||| S:2758 E:2766 ||| NNS
was  ||| S:2766 E:2770 ||| VBD
not  ||| S:2770 E:2774 ||| RB
ideal ||| S:2774 E:2779 ||| JJ
.  ||| S:2779 E:2781 ||| .
In  ||| S:2781 E:2784 ||| IN
conclusion ||| S:2784 E:2794 ||| NN
,  ||| S:2794 E:2796 ||| ,
although  ||| S:2796 E:2805 ||| IN
telbivudine  ||| S:2805 E:2817 ||| NN
was  ||| S:2817 E:2821 ||| VBD
statistically  ||| S:2821 E:2835 ||| RB
superior  ||| S:2835 E:2844 ||| JJ
to  ||| S:2844 E:2847 ||| TO
lamivudine  ||| S:2847 E:2858 ||| VB
for  ||| S:2858 E:2862 ||| IN
most  ||| S:2862 E:2867 ||| RBS
antiviral  ||| S:2867 E:2877 ||| JJ
outcomes ||| S:2877 E:2885 ||| NNS
,  ||| S:2885 E:2887 ||| ,
the  ||| S:2887 E:2891 ||| DT
difference  ||| S:2891 E:2902 ||| NN
was  ||| S:2902 E:2906 ||| VBD
not  ||| S:2906 E:2910 ||| RB
clinically  ||| S:2910 E:2921 ||| RB
significant ||| S:2921 E:2932 ||| JJ
;  ||| S:2932 E:2934 ||| :
in  ||| S:2934 E:2937 ||| IN
addition ||| S:2937 E:2945 ||| NN
,  ||| S:2945 E:2947 ||| ,
the  ||| S:2947 E:2951 ||| DT
cost-effectiveness  ||| S:2951 E:2970 ||| JJ
evidence  ||| S:2970 E:2979 ||| NN
for  ||| S:2979 E:2983 ||| IN
telbivudine  ||| S:2983 E:2995 ||| VBG
presented  ||| S:2995 E:3005 ||| VBN
in  ||| S:3005 E:3008 ||| IN
the  ||| S:3008 E:3012 ||| DT
manufacturer ||| S:3012 E:3024 ||| NN
's  ||| S:3024 E:3027 ||| POS
submission  ||| S:3027 E:3038 ||| NN
was  ||| S:3038 E:3042 ||| VBD
limited ||| S:3042 E:3049 ||| VBN
.  ||| S:3049 E:3051 ||| .
The  ||| S:3051 E:3055 ||| DT
NICE  ||| S:3055 E:3060 ||| NNP
guidance  ||| S:3060 E:3069 ||| VBD
issued  ||| S:3069 E:3076 ||| VBN
as  ||| S:3076 E:3079 ||| IN
a  ||| S:3079 E:3081 ||| DT
result  ||| S:3081 E:3088 ||| NN
of  ||| S:3088 E:3091 ||| IN
the  ||| S:3091 E:3095 ||| DT
STA  ||| S:3095 E:3099 ||| NNP
states  ||| S:3099 E:3106 ||| NNS
that  ||| S:3106 E:3111 ||| IN
telbivudine  ||| S:3111 E:3123 ||| NN
is  ||| S:3123 E:3126 ||| VBZ
not  ||| S:3126 E:3130 ||| RB
recommended  ||| S:3130 E:3142 ||| VBN
for  ||| S:3142 E:3146 ||| IN
the  ||| S:3146 E:3150 ||| DT
treatment  ||| S:3150 E:3160 ||| NN
of  ||| S:3160 E:3163 ||| IN
chronic  ||| S:3163 E:3171 ||| JJ
hepatitis  ||| S:3171 E:3181 ||| NNP
B  ||| S:3181 E:3183 ||| NNP
and  ||| S:3183 E:3187 ||| CC
that  ||| S:3187 E:3192 ||| IN
people  ||| S:3192 E:3199 ||| NNS
currently  ||| S:3199 E:3209 ||| RB
receiving  ||| S:3209 E:3219 ||| VBG
telbivudine  ||| S:3219 E:3231 ||| NNS
should  ||| S:3231 E:3238 ||| MD
have  ||| S:3238 E:3243 ||| VB
the  ||| S:3243 E:3247 ||| DT
option  ||| S:3247 E:3254 ||| NN
to  ||| S:3254 E:3257 ||| TO
continue  ||| S:3257 E:3266 ||| VB
therapy  ||| S:3266 E:3274 ||| NN
until  ||| S:3274 E:3280 ||| IN
they  ||| S:3280 E:3285 ||| PRP
and  ||| S:3285 E:3289 ||| CC
their  ||| S:3289 E:3295 ||| PRP$
clinicians  ||| S:3295 E:3306 ||| NNS
consider  ||| S:3306 E:3315 ||| VBP
it  ||| S:3315 E:3318 ||| PRP
appropriate  ||| S:3318 E:3330 ||| JJ
to  ||| S:3330 E:3333 ||| TO
stop ||| S:3333 E:3337 ||| VB
.  ||| S:3337 E:3339 ||| .
